These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19689280)

  • 61. M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.
    Kishimoto TK; Qi YW; Long A; Capila I; Sasisekharan R; Guerrero L; Fier I; Roach J; Venkataraman G
    Thromb Haemost; 2009 Nov; 102(5):900-6. PubMed ID: 19888526
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
    Clark NP
    Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The use of low-molecular-weight heparins in cardiovascular disease.
    Verhaeghe R
    Acta Cardiol; 1998; 53(1):15-21. PubMed ID: 9638965
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004.
    Siguret V; Pautas E; Gouin I
    Curr Opin Pulm Med; 2004 Sep; 10(5):366-70. PubMed ID: 15316433
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
    Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
    Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS).
    Leizorovicz A; Siguret V; Mottier D; ; Leizorovicz A; Siguret V; Mottier D; Clonier F; Janas M; Stinson J; Townshend G; Maddalena M
    Thromb Res; 2011 Jul; 128(1):27-34. PubMed ID: 21477846
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats.
    Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A
    J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacological strategies for inhibition of thrombin activity.
    Alban S
    Curr Pharm Des; 2008; 14(12):1152-75. PubMed ID: 18473863
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
    Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
    Ornstein DL; Hong-Dice YG; Papini JR
    Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [From heparin to synthetic antithrombotic drugs].
    Palareti G; Cosmi B
    Minerva Anestesiol; 2001 Sep; 67(9 Suppl 1):76-81. PubMed ID: 11778099
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.
    Frydman A
    Haemostasis; 1996; 26 Suppl 2():24-38. PubMed ID: 8707165
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparins.
    Hirsh J
    Curr Opin Hematol; 1998 Sep; 5(5):360-5. PubMed ID: 9776217
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Isolation of a pure octadecasaccharide with antithrombin activity from an ultra-low-molecular-weight heparin.
    Mourier PA; Guichard OY; Herman F; Viskov C
    Anal Biochem; 2014 May; 453():7-15. PubMed ID: 24561026
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Low molecular weight heparin and bleeding in patients with chronic renal failure.
    Crowther M; Lim W
    Curr Opin Pulm Med; 2007 Sep; 13(5):409-13. PubMed ID: 17940486
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Structural Analysis of Heparin-Derived 3-O-Sulfated Tetrasaccharides: Antithrombin Binding Site Variants.
    Chen Y; Lin L; Agyekum I; Zhang X; St Ange K; Yu Y; Zhang F; Liu J; Amster IJ; Linhardt RJ
    J Pharm Sci; 2017 Apr; 106(4):973-981. PubMed ID: 28007564
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Heparins, low-molecular-weight heparins, and pentasaccharides.
    Dinwoodey DL; Ansell JE
    Clin Geriatr Med; 2006 Feb; 22(1):1-15, vii. PubMed ID: 16377464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.